دورية أكاديمية
High measures of pre-chemoradiotherapy platelet-to-albumin ratio indicates poor prognosis in locally advanced pancreatic cancer patients
| العنوان: | High measures of pre-chemoradiotherapy platelet-to-albumin ratio indicates poor prognosis in locally advanced pancreatic cancer patients |
|---|---|
| المساهمون: | Selek, Uğur (ORCID 0000-0001-8087-3140 & YÖK ID 27211), Küçük, A., Topkan, E., Haksöyler, V., Mertsoylu, H., Besen, A.A., Pehlivan, B., School of Medicine |
| المصدر: | Therapeutics and Clinical Risk Management |
| بيانات النشر: | Dove Medical Press International |
| سنة النشر: | 2022 |
| المجموعة: | Koç University Suna Kıraç Library’ Digital Collections |
| مصطلحات موضوعية: | Health care sciences and services, Concurrent chemoradiotherapy, Pancreas cancer, Platelet-to-albumin ratio, Prognosis, Survival outcomes |
| الوصف: | Purpose: in a lack of similar research, we meant to retrospectively investigate the prognostic significance of pre-chemoradiotherapy (C-CRT) platelet-to-albumin ratio (PAR) on the survival results of locally advanced unresectable pancreatic adenocarcinoma (LAPC) patients. Patients and methods: the present analysis included 139 LAPC patients who received C-CRT in total. The utility of pre-C-CRT cutoff(s) reshaping survival data was explored using receiver operating characteristic (ROC) curve analysis. The primary and secondary objectives were the associations between PAR levels and overall survival (OS) and progression-free survival (PFS) outcomes. Results: at a median follow-up of 15.7 months (95% CI: 11.6-19.8), the overall cohort's median and 5-year OS rates were 14.4 months (95% CI: 11.8-17) and 14.7%, respectively, while the corresponding PFS rates were 7.8 months (95% CI: 6.5-9.1) and 11.2%. Because the ROC curve analysis found 4.9 as the optimal PAR cutoff for both OS and PFS [area under the curve (AUC): 75.4%; sensitivity: 72.4%; specificity: 70.3%], we divided the patients into two PAR cohorts: PAR<4.9 (N=60) and PAR>4.9 (N=79). Comparative analysis per PAR group exhibited significantly worse OS (11.2 vs 18.6 months, and 9.8% vs 20.9% at 5 years, P=0.003) and DFS (7 vs 14.3 months, and 7.6% vs 16.2% at 5 years, P=0.001) with PAR>4.9 versus PAR<4.9, respectively. In multivariate analysis, the N0 nodal status, CA 19-9 <= 90 U/mL, and PAR<4.9 were found to be independent predictors of improved OS and PFS. Conclusion: the pre-C-CRT high PAR (>4.9) robustly and independently prognosticated significantly worse OS and PFS results in inoperable LAPC patients who underwent definitive C-CRT. ; NA |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | |
| اللغة: | English |
| تدمد: | 1178-203X |
| العلاقة: | Publisher version; Koç University Institutional Repository; Kucuk, Ahmet, Erkan Topkan, Ugur Selek, Veysel Haksoyler, Huseyin Mertsoylu, Ali Ayberk Besen, and Berrin Pehlivan. ""Significance of Pre-chemoradiotherapy Platelet-to-albumin Ra: TCRM."" Therapeutics and Clinical Risk Management. (2022).; https://dx.doi.org/10.2147/TCRM.S359553Test; IR03651.pdf; WoS; Scopus; PubMed; NA; http://libdigitalcollections.ku.edu.tr/cdm/ref/collection/IR/id/10509Test |
| DOI: | 10.2147/TCRM.S359553 |
| الإتاحة: | https://doi.org/10.2147/TCRM.S359553Test http://libdigitalcollections.ku.edu.tr/cdm/ref/collection/IR/id/10509Test |
| رقم الانضمام: | edsbas.69A4454 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 1178203X |
|---|---|
| DOI: | 10.2147/TCRM.S359553 |